Related Experiment Video
Updated: May 5, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
[MicroRNA in neurodegenerative disorders]
1Department of Neurology, Nagoya University Graduate School of Medicine.
Abstract:
MicroRNAs (miRNAs) bind to the 3'-untranslated region of mRNA, and thereby suppress the gene expression. Recent studies suggest that miRNAs modify the pathogenesis of cancer and neurodegeneration. Our study demonstrated that the expression levels of miR-196a is increased in a mouse model of spinal and bulbar muscular atrophy (SBMA), a neurodegenerative disease caused by the expansion of polyglutamine in androgen receptor (AR). In cultured neuronal cells, miR-196a decayed the mutant AR mRNA via silencing CUG triplet repeat RNA binding protein 2, a potent miR-196a targeting mRNA, which contributed to stabilize the mutant AR mRNA. Adeno-associated virus vector-mediated delivery of this miRNA attenuates the expression of the mutant AR, resulting in the mitigation of motor neuron degeneration in the SBMA mice. Introduction of miRNA appears to be a novel therapeutic strategy for devastating neurodegenerative diseases.
Insights
MicroRNAs (miRNAs) can treat neurodegenerative diseases like spinal and bulbar muscular atrophy (SBMA). This study shows miR-196a therapy reduces mutant androgen receptor (AR) in SBMA mice, mitigating motor neuron loss.
Area of Science:
- Molecular Biology
- Neuroscience
- Genetics
Context:
- MicroRNAs (miRNAs) regulate gene expression by targeting mRNA, influencing various cellular processes.
- Neurodegenerative diseases, including spinal and bulbar muscular atrophy (SBMA), are linked to altered gene expression and protein aggregation.
- SBMA is caused by polyglutamine expansion in the androgen receptor (AR), leading to motor neuron degeneration.
Purpose:
- To investigate the role of miR-196a in the pathogenesis of SBMA.
- To explore the therapeutic potential of miR-196a delivery for SBMA treatment.
Summary:
- This study found elevated miR-196a levels in an SBMA mouse model.
- miR-196a was shown to degrade mutant AR mRNA by targeting CUG triplet repeat RNA binding protein 2, which stabilizes mutant AR.
- Adeno-associated virus-mediated delivery of miR-196a reduced mutant AR expression and mitigated motor neuron degeneration in SBMA mice.
Impact:
- MicroRNA-based therapies offer a novel strategy for treating neurodegenerative diseases.
- This research highlights miR-196a as a potential therapeutic agent for SBMA.
- The findings contribute to understanding miRNA-mediated gene regulation in neurodegeneration.
More Related Videos
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
MicroRNAs
MicroRNAs
MicroRNAs
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer Disease l: Introduction

